LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia
Patients from Multiple Myeloma Patients

J 2021

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI et. al.

Basic information

Original name

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

Authors

BÚTOVÁ, Romana (703 Slovakia, belonging to the institution), Petra VYCHYTILOVÁ (203 Czech Republic, belonging to the institution), Jana GREGOROVÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Martina ALMASI (203 Czech Republic), Renata BEZDEKOVA (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Zdenka KNECHTOVA (203 Czech Republic), Martin ŠTORK (203 Czech Republic), Luděk POUR (203 Czech Republic) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomedicines, Basel, MDPI, 2021, 2227-9059

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.757

RIV identification code

RIV/00216224:14110/21:00123611

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/biomedicines9111637

UT WoS

000725844800001

Keywords in English

multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression

Abstract

V originále

Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.

Links

MUNI/A/1698/2020, interní kód MU

Name: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF)

Investor: Masaryk University

Citovat

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. Basel: MDPI, 2021, vol. 9, No 11, p. 1-11. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9111637.

@article{1818659,
   author = {Bútová, Romana and Vychytilová, Petra and Gregorová, Jana and Radová, Lenka and Almasi, Martina and Bezdekova, Renata and Brožová, Lucie and Jarkovský, Jiří and Knechtova, Zdenka and Štork, Martin and Pour, Luděk and Ševčíková, Sabina},
   article_location = {Basel},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/biomedicines9111637},
   keywords = {multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression},
   language = {eng},
   issn = {2227-9059},
   journal = {Biomedicines},
   title = {LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients},
   url = {https://www.mdpi.com/2227-9059/9/11/1637},
   volume = {9},
   year = {2021}
}

TY  - JOUR
ID  - 1818659
AU  - Bútová, Romana - Vychytilová, Petra - Gregorová, Jana - Radová, Lenka - Almasi, Martina - Bezdekova, Renata - Brožová, Lucie - Jarkovský, Jiří - Knechtova, Zdenka - Štork, Martin - Pour, Luděk - Ševčíková, Sabina
PY  - 2021
TI  - LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
JF  - Biomedicines
VL  - 9
IS  - 11
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 22279059
KW  - multiple myeloma
KW  - plasma cell leukemia
KW  - long non-coding RNA
KW  - next-generation sequencing
KW  - biomarkers
KW  - disease progression
UR  - https://www.mdpi.com/2227-9059/9/11/1637
N2  - Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
ER  -

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. \textit{Biomedicines}. Basel: MDPI, 2021, vol.~9, No~11, p.~1-11. ISSN~2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9111637.

Detailed Information on Publication Record